Does Rallies show 13F holders for TERN?

Yes. Rallies tracks hedge fund and 13F ownership data for TERN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is TERN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TERN. It does not provide personalized investment advice.

TERN (Terns Pharmaceuticals, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Terns Pharmaceuticals, Inc. Common Stock (TERN) is a publicly traded Healthcare sector company. As of May 20, 2026, TERN trades at $52.95 with a market cap of $6.12B and a P/E ratio of -51.41. TERN moved +0.07% today. Year to date, TERN is +23.37%; over the trailing twelve months it is +1412.86%. Its 52-week range spans $1.87 to $53.19. Analyst consensus is neutral with an average price target of $52.97. Rallies surfaces TERN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns TERN stock?

Hedge funds tracked by Rallies that own TERN include Orbimed Advisors, Sculptor Capital, Soros Fund, Davidson Kempner, and Fortress Investment. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Terns Pharmaceuticals, Inc. Common Stock.

TERN Key Metrics

Key financial metrics for TERN
Metric	Value
Price	$52.95
Market Cap	$6.12B
P/E Ratio	-51.41
EPS	$-1.03
Dividend Yield	0.00%
52-Week High	$53.19
52-Week Low	$1.87
Volume	0
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-96.21M
Gross Margin	0.00%

Top Hedge Funds Holding TERN

Orbimed Advisors holds 2.15M shares of TERN, changed -71.53% as of Dec 31, 2025.
Sculptor Capital holds 380.00K shares of TERN, changed +0.00% as of Mar 31, 2026.
Soros Fund holds 321.90K shares of TERN, changed +0.00% as of Mar 31, 2026.
Davidson Kempner holds 311.62K shares of TERN, changed +0.00% as of Mar 31, 2026.
Fortress Investment holds 30.00K shares of TERN, changed +0.00% as of Mar 31, 2026.

Latest TERN News

Merck Completes Terns Acquisition at $53 Per Share, Gains CML Breakthrough — May 6, 2026
Terns Secures FDA Breakthrough Designation for TERN-701, Merck Deal to Accelerate Trials — Apr 27, 2026
Terns Pharmaceuticals $53 Cash Sale to Merck Faces Fiduciary Probe — Apr 9, 2026
Merck to Acquire Terns for $6.7bn, Highlighting TERN-701’s 75% MMR in CML — Mar 30, 2026
Terns Pharmaceuticals’ $53 Cash Sale to Merck Faces Legal Scrutiny — Mar 26, 2026

Recent TERN Insider Trades

Kuriakose Emil sold 942 (~$49.69K) on Apr 1, 2026.
Burroughs Amy L. sold 11.81K (~$550.08K) on Mar 16, 2026.
Burroughs Amy L. sold 2.77K (~$131.03K) on Mar 16, 2026.

TERN Analyst Consensus

6 analysts cover TERN: 0 strong buy, 0 buy, 6 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $52.97.

Common questions about TERN

Who owns TERN stock?: Hedge funds tracked by Rallies that own TERN include Orbimed Advisors, Sculptor Capital, Soros Fund, Davidson Kempner, and Fortress Investment. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Terns Pharmaceuticals, Inc. Common Stock.
Does Rallies show 13F holders for TERN?: Yes. Rallies tracks hedge fund and 13F ownership data for TERN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is TERN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TERN. It does not provide personalized investment advice.